Advertisement

Topics

NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology

11:00 EST 3 Dec 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Novel Trisprcific CD19.t-haNKTM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company...

Other Sources for this Article

NantKwest
Media Contact:
Jen Hodson
562-397-3639
Jen@nant.com

Investor Contact:
David Pyrce
951-551-0949
david.pyrce@nantkwest.com

NEXT ARTICLE

More From BioPortfolio on "NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...